免疫检查点抑制剂相关性肺炎放射学特点和诊疗——2018年ASCO指南：放射科医师入门 ... ...

概述：

Introduction

Since its first FDA approval in 2011, the use of immune checkpoint inhibitors (ICI) has rapidly expanded

自2011年首次获得FDA批准以来，免疫检查点抑制剂（ICI）的使用迅速扩大

ICIs are now standard therapies for a variety of malignancies with ongoing investigation in many clinical trials

• Current approval: melanoma, NSCLC, RCC, Merkel cell carcinoma, urothelial cancers, Hodgkin’s lymphoma

ICI现在是各种恶性肿瘤的标准疗法，在许多临床试验中正在进行研究

•目前批准：黑色素瘤，NSCLC，RCC，Merkel细胞癌，尿路上皮癌，霍奇金淋巴瘤

Because of the unique mechanism of actions of ICIs relative to standard chemotherapies, new treatment response and toxicity patterns are becoming more prevalent.

由于ICI相对于标准化学疗法的独特作用机制，新的治疗反应和毒性模式正变得越来越普遍。

Immune Mediated Tumor Response

免疫介导的肿瘤反应

Wang GX, et al. Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings.Radiographics. 2017;37(7):2132-2144. doi: 10.1148/rg.2017170085. Review.PMID: 29131763.